NCT00459862 · OUTCOME

Overall Survival

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma · Source last updated 2015-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: From study enrollment to time of death from any cause or censored at last follow-up, up to 3 years

Analysis population: All 34 participants were evaluable for this endpoint.

Groups in this outcome

Arm I

Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I	34

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Arm I	11.5	Not reported	6.2	18.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
6.2
upper Limit
18.2
value
11.5

denoms

counts
group Id
OG000
value
34
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Arm I

param Type

MEDIAN

population Description

All 34 participants were evaluable for this endpoint.

reporting Status

POSTED

time Frame

From study enrollment to time of death from any cause or censored at last follow-up, up to 3 years

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice